PHARMACEUTICAL 2023

Bristol Myers Squibb CO
Rank 273 of 471



PHARMACEUTICAL 2023

Bristol Myers Squibb CO
Rank 273 of 471

The relative strengths and weaknesses of Bristol Myers Squibb CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bristol Myers Squibb CO compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 86% points.The greatest weakness of Bristol Myers Squibb CO is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 94% points.

The company's Economic Capital Ratio, given in the ranking table, is 223%, being 22% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	27,273,000
Cost of Goods Sold	10,137,000
Intangible Assets	57,008,000
Liabilities, Current	21,890,000
Liabilities, Non-Current	41,646,000
Other Assets	6,284,000
Other Compr. Net Income	-31,000
Other Expenses	12,354,000
Other Liabilities	2,166,000
Other Net Income	0
Other Revenues	46,159,000
Property and Equipment	6,255,000
Research and Development	9,509,000
Selling, General and Administrative Expense	7,814,000

Output Variable	Value in 1000 USD
Assets	96,820,000
Liabilities	65,702,000
Expenses	39,814,000
Revenues	46,159,000
Stockholders Equity	31,118,000
Net Income	6,345,000
Comprehensive Net Income	6,329,500
BaseVar	124,263,000
ECR before LimitedLiability	91%
Economic Capital Ratio	223%